Inflammatory bowel disease: clinical aspects
DOI:
https://doi.org/10.15584/ejcem.2018.4.12Keywords:
inflammatory bowel diseases, Leśniowski-Crohn’s disease, ulcerative colitis, mataloproteinasesAbstract
Introduction. Inflammatory bowel disease is a complex disease which arises as a result of an interaction between environmental and genetic factors leading to immunological responses and inflammation in the intestine.
Aim. To review medical approaches used in inflammatory bowel disorders.
Material and methods. An analysis of literature regarding inflammatory bowel diseases, Leśniowski-Crohn’s disease, ulcerative colitis and mataloproteinases.
Results. Current evidence suggests that patients with inflammatory bowel disease may have an elevated risk of endothelial dysfunction and coronary artery disease. Over the past two decades, great advances have been made in our understanding of the interplay between the inflammatory bowel disease.
Conclusion. Inflammatory bowel diseases are increasing in Europe. The diagnosis is usually confirmed by biopsies on colonoscopy.
Downloads
References
Skok P, Skok K. Acute febrile neutrophilic dermatosis in a patient with Crohn's disease: case report and review of the literature. Acta Dermatovenerol Alp Pannonica Adriat. 2018;27(3):161-163.
Harris KG, Chang EB. The intestinal microbiota in the pathogenesis of inflammatory bowel diseases: new insights into complex disease. Clin Sci (Lond). 2018;132(18):2013-2028.
Florin THJ, Wright JD, Jambhrunkar SD, Henman MG, Popat A. A well-tolerated and rapidly acting thiopurine for IBD? Drug Discov Today. 2018; pii: S1359-6446(18)30290-3.
Kaida-Yip F, Deshpande K, Saran T, Vyas D. Biosimilars: Review of current applications, obstacles, and their future in medicine. World J Clin Cases. 2018;6(8):161-166
Szántó K, Nyári T, Bálint A, et al. Biological therapy and surgery rates in inflammatory bowel diseases - Data analysis of almost 1000 patients from a Hungarian tertiary IBD center. PLoS One. 2018;13(7):e0200824.
Stawiski K, Strzałka A, Puła A, Bijakowski K. PancreApp: An Innovative Approach to Computational Individualization of Nutritional Therapy in Chronic Gastrointestinal Disorders. Stud Health Technol Inform. 2015; 216:325-328.
Lu B, Niu LL, Xu XG, Yao SL, Tan XY. Ulcerative colitis in an adult patient mimicking Henoch-Schönlein purpura: A case report. Medicine (Baltimore). 2018;97(35):e12036.
Aytac E, Ozuner G, Isik O, Gorgun E, Remzi FH. Surgical management of patients with ulcerative colitis during pregnancy: maternal and fetal outcomes. J Crohns Colitis. 2015;9(1):82-85.
Mattioli G, Barabino A, Aloi M, et al. Paediatric ulcerative colitis surgery: Italian survey. J Crohns Colitis. 2015;9(7):558-566.
Burke KE, Haviland MJ, Hacker MR, Shainker SA, Cheifetz AS. Indications for Mode of Delivery in Pregnant Women with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23(5):721-726.
Ashton JJ, Ennis S, Beattie RM. Early-onset paediatric inflammatory bowel disease. Lancet Child Adolesc Health. 2017;1(2):147-158.
Singeap AM, Stanciu C, Cojocariu C, Sfarti C, Trifan A. Capsule Endoscopy in Inflammatory Bowel Disease: Current Applications. Arch Iran Med. 2015;18(6):379-383.
Palkovits J, Novacek G, Kollars M, et al. Tissue factor exposing microparticles in inflammatory bowel disease. Journal of Crohn’s & Colitis. 2013;7(3): 222–229.
Saluk J, Bijak M, Ponczek MB, Wachowicz B. The formation, metabolism and the evolution of blood platelets. Postȩpy Higieny i Medycyny Doświadczalnej. 2014;68: 384–392.
Zatorski H, Sałaga M, Zielińska M, Fichna J. Genetic factors in pathogenesis, course and treatment of inflammatory bowel diseases. Postępy Higieny i Medycyny Doświadczalnej. 2015; 69:335–344.
Fakhoury M, Negrulj R, Mooranian A, al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014; 7:113–120.
Cioffi M, Rosa AD, Serao R, Picone I, Vietri MT. Laboratory markers in ulcerative colitis: current insights and future advances. World J Gastrointestinal Pathophysiol. 2015; 6(1):13–22.
Thorsvik S, Damås JK, Granlund AB. Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease. J Gastroenterol Hepatol. 2017; 32(1): 128–135.
Vatn MH, Sandvik AK. Inflammatory bowel disease. Scandinav J of Gastroenterol. 2015;50(6) 748–762.
Acevedo D, Salvador MP, Girbes J, Estan N. Fecal calprotectin: a comparison of two commercial enzymoimmunoassays and study of fecal extract stability at room temperature. J Clin Med Res. 2018; 10(5), 396–404.
Lallemand C, Liang F, Staub F, Simansour M, Vallette B, Huang L, Ferrando-Miguel R, Tovey MG. A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies. J Immunol Res. 2017;2017:3908289.
Abraham BP, Thirumurthi S. Clinical significance of inflammatory markers. Curr Gastroenterol Rep. 2009;11(5):360-367.
Malícková K, Janatková I, Fucíková T, Adamec S, Lukás M. Initial experience with detection of Saccharomyces cerevisiae antibodies in patients with primary nonspecific inflammatory bowel disease. Epidemiol Mikrobiol Imunol. 2001;50(3):131-135.
Eda K, Mizuochi T, Takaki Y, Ushijima K, Umeno J, Yamashita Y. Successful azathioprine treatment in an adolescent with chronic enteropathy associated with SLCO2A1 gene: A case report. Medicine (Baltimore). 2018;97(41):e12811.
Umeno J, Matsumoto T, Hirano A, Fuyuno Y, Esaki M. Genetic analysis is helpful for the diagnosis of small bowel ulceration. World J Gastroenterol. 2018;24(28):3198-3200.
Derkacz A, Olczyk P, Komosinska-Vassev K. Diagnostic Markers for Nonspecific Inflammatory Bowel Diseases. Dis Markers. 2018;2018:7451946.
Shivashankar R, Lichtenstein GR. Mimics of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24(11):2315-2321.
You JY. Features and management of very early onset inflammatory bowel disease. Zhongguo Dang Dai Er Ke Za Zhi. 2018;20(5):341-345.
Mang T, Scharitzer M. Imaging of gastrointestinal inflammation: Characteristic patterns and signs. Radiologe. 2018;58(4):281-291.
Gupta AS, Nunley JR, Feldman MJ, Ortega-Loayza AG. Pyoderma Gangrenosum of the Scalp: A Rare Clinical Variant. Wounds. 2018;30(2):16-20.
Yamada Y, Sugimoto K, Yoshizawa Y, et al. Mesenteric inflammatory veno-occlusive disease occurring during the course of ulcerative colitis: a case report. BMC Gastroenterol. 2018; 11;18(1):9.
Klimczak K, Lykowska-Szuber L, Eder P, et al. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity. Eur J Intern Med. 2015;26(8):623-627.
Truffi M, Sorrentino L, Monieri M, et al. Inhibition of Fibroblast Activation Protein Restores a Balanced Extracellular Matrix and Reduces Fibrosis in Crohn's Disease Strictures Ex Vivo. Inflamm Bowel Dis. 2018;24(2):332-345.
van der Smissen A, Hintze V, Scharnweber D, et al. Growth promoting substrates for human dermal fibroblasts provided by artificial extracellular matrices composed of collagen I and sulfated glycosaminoglycans. Biomaterials. 2011;32(34):8938-8946.
Nakahara Y, Matsusaki M, Akashi M. Fabrication and enzymatic degradation of fibronectin-based ultrathin films. Fabrication and enzymatic degradation of fibronectin-based ultrathin films. J Biomater Sci Polym Ed. 2007;18(12):1565-1573.
Matsushima H, Bogenmann E. Modulation of neuroblastoma cell differentiation by the extracellular matrix. Int J Cancer. 1992;51(5):727-732.
Kliemt S, Lange C, Otto W, et al. Sulfated hyaluronan containing collagen matrices enhance cell-matrix-interaction, endocytosis, and osteogenic differentiation of human mesenchymal stromal cells. J Proteome Res. 2013;12(1):378-389.
Klimczak K, Lykowska-Szuber L, Eder P, et al. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity. Eur J Intern Med. 2015;26(8):623-627.
Petrey AC, de la Motte CA. Hyaluronan in inflammatory bowel disease: cross-linking inflammation and coagulation. Matrix Biology. 2018; 1461: 4C.
Koutroubakis IE, Petinaki E, Dimoulios P. Serum laminin and collagen IV in inflammatory bowel disease. J Clin Pathol. 2003: 56(11):817–820.
Hundorfean G, Neurath MF, Sitaru C. Autoimmunity against type VII collagen in inflammatory bowel disease. J Cell Mol Med. 2010;14(10):2393–2403.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
